CMAC National Facility - Drug Product and Secondary Manufacturing

Faster, evidence-based decisions from raw material to finished form

Formulation and process decisions made late or on limited data put development at risk. Scale-up failures, poor solubility and difficult powders delay timelines, consume scarce API and weaken regulatory confidence.

WHAT SETS US APART

Every processing route, from first milligram to pilot scale

Our integrated facility spans the full drug product manufacturing landscape, from raw material characterisation through granulation, tableting, hot melt extrusion and 3D printing. Whatever your processing route, we have the equipment, expertise and research depth to support it.

Scientists who work on your problem, not just your samples

Our teams design studies around your specific formulation and manufacturing challenges, interpreting data, connecting results to your decisions and drawing on the full breadth of CMAC's multidisciplinary expertise.

PROCESSING AND ANALYTICAL PLATFORMS

Seven capabilities. One integrated facility.

Not sure which platform you need?

Our experts will advise on the best approach for your formulation and process.

APPLICATIONS AND IMPACT

We work across the full spectrum of drug product challenges:

Bioavailability enhancement for poorly soluble drugs via amorphous solid dispersions

Continuous manufacturing process development and batch-to-continuous transfer

Drug product characterisation for regulatory submissions

Lubrication, feedframe and compaction sensitivity studies at minimal material

Oral solid dosage form development — tablets, granules, capsules and printed forms

Scale-up risk assessment from lab to pilot to industrial scale

Ready to collaborate?

Email icon, a black envelope inside a white circle.

Whether you're exploring new drug products or solving complex process challenges, we are here to help.

CMAC has achieved two Silver and one Bronze level certifications for integrating sustainable practices in its lab operations.